Prognosis Evaluation Using ¹⁸F-Alfatide II PET in a Rat Model of Spinal Cord Injury Treated With Estrogen.

IF 2.8 4区医学 Q2 Medicine

Molecular Imaging Pub Date : 2020-01-01 DOI:10.1177/1536012120909199

Hongpei Tan, Yongxiang Tang, Jian Li, Tingting He, Ming Zhou, Shuo Hu

{"title":"Prognosis Evaluation Using 18F-Alfatide II PET in a Rat Model of Spinal Cord Injury Treated With Estrogen.","authors":"Hongpei Tan, Yongxiang Tang, Jian Li, Tingting He, Ming Zhou, Shuo Hu","doi":"10.1177/1536012120909199","DOIUrl":null,"url":null,"abstract":"Spinal cord injury (SCI) leads to severe dysfunction below injured segment and poses a great pressure to the individual and society. In this study, we applied 18F-alfatide II positron emission tomography/computed tomography (PET/CT) to monitor angiogenesis in an SCI model after estrogen (E2) treatment, as well as to evaluate the prognosis in a noninvasive manner. The SCI model was established with male rats and the rats were randomly divided into E2-treated group (SCI + E2) and E2-untreated group (SCI). Sham group was also used as control (Sham). The angiogenesis after SCI was monitored by 18F-alfatide II PET/CT and verified by immunofluorescence of CD31 and CD61. We also evaluated the level of E2 and growth-associated protein 43 (GAP43) by enzyme-linked immunosorbent assay. Finally, Basso, Beattie, and Bresnahan (BBB) scores were determined to evaluate the exercise capacity of the rats in all 3 groups. Our results showed that the BBB score of SCI + E2 group was significantly different from that of SCI group (P < .05) and Sham group (P < .01). The uptake of 18F-alfatide II was positively correlated with the expression level of GAP43, both of which reached the peak at day 7 after injury. CD31 and CD61 immunostaining further verified increased angiogenesis in E2-treated SCI lesions. We concluded that 18F-alfatide II PET/CT can monitor the angiogenesis status after SCI in vivo and it may help clinician predict the progression of patients with SCI. This may benefit the study of vascular repair after SCI and provide a tool for evaluation of SCI treatment in clinical practices.","PeriodicalId":49796,"journal":{"name":"Molecular Imaging","volume":"19 ","pages":"1536012120909199"},"PeriodicalIF":2.8000,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1177/1536012120909199","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Molecular Imaging","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/1536012120909199","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 2

Abstract

Spinal cord injury (SCI) leads to severe dysfunction below injured segment and poses a great pressure to the individual and society. In this study, we applied ¹⁸F-alfatide II positron emission tomography/computed tomography (PET/CT) to monitor angiogenesis in an SCI model after estrogen (E2) treatment, as well as to evaluate the prognosis in a noninvasive manner. The SCI model was established with male rats and the rats were randomly divided into E2-treated group (SCI + E2) and E2-untreated group (SCI). Sham group was also used as control (Sham). The angiogenesis after SCI was monitored by ¹⁸F-alfatide II PET/CT and verified by immunofluorescence of CD31 and CD61. We also evaluated the level of E2 and growth-associated protein 43 (GAP43) by enzyme-linked immunosorbent assay. Finally, Basso, Beattie, and Bresnahan (BBB) scores were determined to evaluate the exercise capacity of the rats in all 3 groups. Our results showed that the BBB score of SCI + E2 group was significantly different from that of SCI group (P < .05) and Sham group (P < .01). The uptake of ¹⁸F-alfatide II was positively correlated with the expression level of GAP43, both of which reached the peak at day 7 after injury. CD31 and CD61 immunostaining further verified increased angiogenesis in E2-treated SCI lesions. We concluded that ¹⁸F-alfatide II PET/CT can monitor the angiogenesis status after SCI in vivo and it may help clinician predict the progression of patients with SCI. This may benefit the study of vascular repair after SCI and provide a tool for evaluation of SCI treatment in clinical practices.

Abstract Image

查看原文本刊更多论文

18F-Alfatide II PET对雌激素治疗大鼠脊髓损伤模型的预后评价。

脊髓损伤导致损伤节段以下出现严重功能障碍，给个人和社会带来巨大压力。在本研究中，我们应用18F-alfatide II正电子发射断层扫描/计算机断层扫描(PET/CT)监测雌激素(E2)治疗后脊髓损伤模型的血管生成情况，并以无创方式评估预后。以雄性大鼠建立脊髓损伤模型，随机分为E2治疗组(SCI + E2)和E2未治疗组(SCI)。假手术组为对照组(Sham)。采用18F-alfatideⅱPET/CT监测脊髓损伤后血管生成情况，并采用CD31和CD61免疫荧光检测。我们还通过酶联免疫吸附法评估了E2和生长相关蛋白43 (GAP43)的水平。最后采用BBB (Basso, Beattie, and Bresnahan)评分评价三组大鼠的运动能力。结果显示，SCI + E2组BBB评分与SCI组、Sham组比较差异有统计学意义(P < 0.05)。18F-alfatide II的摄取与GAP43的表达水平呈正相关，均在伤后第7天达到峰值。CD31和CD61免疫染色进一步证实e2治疗的脊髓损伤血管生成增加。我们认为18F-alfatide II PET/CT可以在体内监测脊髓损伤后血管生成状态，有助于临床医生预测脊髓损伤患者的病情进展。这可能有利于脊髓损伤后血管修复的研究，并为临床评价脊髓损伤治疗提供工具。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Molecular Imaging 生物-核医学

CiteScore

4.50

自引率

3.60%

发文量

审稿时长

>12 weeks

期刊介绍： Molecular Imaging is a peer-reviewed, open access journal highlighting the breadth of molecular imaging research from basic science to preclinical studies to human applications. This serves both the scientific and clinical communities by disseminating novel results and concepts relevant to the biological study of normal and disease processes in both basic and translational studies ranging from mice to humans.